ArticleBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2020
Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study.
Stephanie L Ho et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.